Phaseline

Companies › SpliSense

SpliSense: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Respiratory; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPL84
RNA splicing modulator for cystic fibrosis
–Phase 2Cystic FibrosisOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06429176SPL84Phase 2Cystic FibrosisRespiratoryOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA Aimmune Nestlé Health Science US R&D Vicore Pharma ReCode Therapeutics Anagram Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.